Clinical Trial Update: Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating a Cadonilimab-based combination as first-line therapy for metastatic HER2-expressing gastric or gastroesophageal juncti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Cadonilimab

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Metastatic HER2 Positive Gastroesophageal Junction Cancer | Phase 1, Phase 2 | Status: RECRUITING